Prof. dr. Ph. Scheltens
VUmc Alzheimer Center
The Dutch Flutemetamol in Young Onset Dementia Study
Neuropathologically, Alzheimers Disease (AD) is characterized by amyloid plaques and neurofibrillary tangles. Development of the positron emission tomography (PET) tracer [11C]Pittsburgh compound-B ([11C]PIB) has for the first time enabled the visualization of amyloid-beta (A?) in vivo, and evidence shows high sensitivity and specificity in separating AD from controls. However, [11C]PIB-PET can only be used where an on-site cyclotron is available for production, hampering its widespread implementation. [18F]-tracers, which do not require on-site production are therefore more suitable to be used by many more centers and enable studying the discriminatory value in the clinical setting. Recently, [18F]Flutemetamol has become available for study. In the present study we aim to establish the clinical value of [18F]Flutemetamol PET imaging in patients with young onset dementia, in which a firm and accurate diagnosis of AD constitutes an important first step in future management. The clinical value of [18F]Flutemetamol PET in patients with young onset dementia will be investigated in terms of 1) change in (level of confidence of) diagnosis; 2) impact on patient healthcare management; 3) diagnostic accuracy of final diagnosis at 2 years follow-up; and 4) cost-effectiveness.